- Home
- CRVO vs MDXH Comparison
CRVO vs MDXH Comparison
Compare CRVO & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CRVO | MDXH |
|---|---|---|
| Founded | 2001 | 2003 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.9M | 41.1M |
| IPO Year | 2011 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CRVO | MDXH |
|---|---|---|
| Price | $4.13 | $0.55 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | ★ $23.00 | $7.67 |
| AVG Volume (30 Days) | ★ 9.5M | 730.8K |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,006,510.00 | N/A |
| Revenue This Year | N/A | $30.78 |
| Revenue Next Year | N/A | $18.31 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.13 | $0.51 |
| 52 Week High | $13.13 | $5.33 |
Technical Indicators
Market Signals| Indicator | CRVO | MDXH |
|---|---|---|
| Relative Strength Index (RSI) | 61.60 | 20.90 |
| Support Level | $3.92 | $0.51 |
| Resistance Level | $4.27 | $3.79 |
| Average True Range (ATR) | 0.83 | 0.07 |
| MACD | 0.17 | 0.05 |
| Stochastic Oscillator | 34.33 | 12.62 |
Price Performance
Historical ComparisonAbout CRVO CervoMed Inc.
CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod, has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.
About MDXH MDxHealth SA
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.